Actively Recruiting
Study of BMS-986504 Combined With Pemetrexed for Treating Metastatic Solid Tumors With MTAP Deletion
Led by Northwestern University · Updated on 2026-08-25
72
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are studying the combination of BMS-986504, a PRMT5 inhibitor, with pemetrexed to evaluate safety, side effects, and effectiveness in treating patients who have metastatic solid tumors with MTAP gene deletion. MTAP deletion affects the cells ability to recycle parts needed for DNA production, which is essential for cell growth. This phase IbII trial aims to better understand how this drug combination works in this specific patient group. Participants receive BMS-986504 as a daily oral dose for 21 days and pemetrexed as an intravenous infusion on the first day of each 21-day cycle. Treatment cycles continue unless disease progression or unacceptable side effects occur. During the study, patients will have blood samples taken and undergo CT scans to monitor their condition. Throughout the trial, participants will be closely monitored for safety, including side effects and serious adverse events, with follow-up visits 30 days after treatment ends and every 3 months for up to a year. Researchers will assess treatment response, duration of response, overall survival, and progression-free survival. The total participation duration depends on individual treatment outcomes and follow-up assessments.
CONDITIONS
Brief Title
BMS-986504 in Combination With Pemetrexed for the Treatment of Metastatic Solid Tumors With MTAP Deletion
Research Team
S
Study Coordinator
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here